Research To Practice | Oncology Videos

Latest Episodes:

Paroxysmal Nocturnal Hemoglobinuria | Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria Apr 26, 2024

Show notes

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics:

Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00)
Biology and Current Clinical Management of PNH (36:35)
Future Directions in PNH Management (55:34)
Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26)

CME information and select publications

Prostate Cancer | Oncology Today with Dr Neil Love: Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers Symposium Apr 25, 2024

Show notes

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics:

Perspectives on advances in the management of prostate cancer over the last decade (0:00)
Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39)
EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25)
Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20)
Management of locally advanced prostate cancer with and without biochemical recurrence (23:58)
PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35)
CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41)
Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38)
Other potential novel therapeutic strategies for prostate cancer (42:28)
Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57)
Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49)
Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44)

CME information and select publications

Myeloproliferative Neoplasms | Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences Apr 24, 2024

Show notes

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)

CME information and select publications

Pancreatic Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O'Reilly, including the following topics.

Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00)
Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O'Reilly (31:46)

CME information and select publications

Colorectal Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics.

Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00)
HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler (25:17)

CME information and select publications

Hepatobiliary Cancers | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics.

Introduction (0:00)
Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30)
Biliary Tract Cancers (BTCs) — Dr Finn (33:16)

CME information and select publications

Gastroesophageal Cancers | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics.

Current and Potential Role of Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancers — Dr Klempner (0:00)
Other Available and Emerging Therapeutic Approaches — Dr Janjigian (31:42)

CME information and select publications

Multiple Myeloma | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics.

Introduction (0:00)
Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates in Multiple Myeloma (MM) — Dr Callander (8:25)
Integration of Other Novel Therapies into the Management of Newly Diagnosed and Relapsed/Refractory MM — Dr Richardson (31:52)

CME information and select publications

Nontargeted Treatments for Lung Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Edward B Garon and Dr Corey J Langer, including the following topics.

Role of Immune Checkpoint Inhibitors in Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Langer (0:00)
Immune Checkpoint Inhibitors and Other Emerging Therapeutic Approaches for Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon (30:08)

CME information and select publications

Targeted Therapy for Non-Small Cell Lung Cancer | Third Annual National General Medical Oncology Summit Apr 19, 2024

Show notes

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Henela Yu, including the following topics.

Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Yu (0:00)
Care of Individuals with Other Targetable Genomic Abnormalities — Dr Dagogo-Jack (31:01)

CME information and select publications